Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimburse...

Source: Respiratory Research - May 4, 2021 Category: Respiratory Medicine Authors: Manon Belhassen, Faustine Dalon, Ma ëva Nolin and Eric Van Ganse Tags: Research Source Type: research